Clinical Roundup UTSW-led study shows promise for upper urinary tract cancer drug January 06, 2023Vol.49 No.01
Clinical Roundup UTSW immunologists uncover obesity-linked trigger to severe form of liver disease January 06, 2023Vol.49 No.01
Clinical Roundup Interim results from OPTIMIZE-1 phase II study show >50% ORR in pancreatic cancer January 06, 2023Vol.49 No.01
Clinical Roundup IU research points to a biomarker for cardiotoxicity in breast cancer–and a role for dexamethasone January 06, 2023Vol.49 No.01
Clinical Roundup Johns Hopkins study identifies gene mechanism in most aggressive kidney cancers January 06, 2023
Clinical Roundup Imbruvica + venetoclax demonstrates efficacy and sustained response in older patients with previously untreated CLL December 16, 2022Vol.48 No.45
Clinical Roundup Phase III study shows long-term results of Darzalex-based regimen in newly diagnosed, transplant-ineligible MM December 16, 2022Vol.48 No.45
Clinical Roundup Phase II data on Regeneron’s linvoseltamab show clinically meaningful responses in heavily pre-treated MM December 16, 2022Vol.48 No.45
Clinical Roundup Positive phase II data reported on Regeneron’s odronextamab in R/R DLBCL December 16, 2022Vol.48 No.45
Clinical Roundup Kisqali prolonged PFS for metastatic breast cancer vs. chemo December 09, 2022Vol.48 No.44
